Denosumab

Overview

4.7 out of 5 (23 Reviews)

Credits

1.00

Post Assessment Questions

5

Start Date

1 Jan 2021

Last Review Date

28 Feb 2024

Expiration Date

31 Dec 2023

Estimated Time To Finish

60 Minutes


 
Need Help?  If you have a system or content concerns, please contact support@statpearls.com

Activity Description

Denosumab, a bone anti-resorptive medication, treats osteoporosis and various bone-related disorders. Its FDA-approved applications span a spectrum of conditions, encompassing the prevention of skeletal-related events such as bone pain and fractures arising secondary to multiple myeloma or bone metastases from solid tumors, giant cell tumors of the bone, hypercalcemia of malignancy, osteoporosis in postmenopausal women at high fracture risk, and men facing an increased risk of fracture due to osteoporosis or glucocorticoid-induced bone loss. This activity focuses on elucidating denosumab's mechanism of action, adverse event profile, toxicity considerations, optimal dosing strategies, pharmacodynamics, and the essential parameters for diligent monitoring. Interprofessional team members will increase their understanding of when denosumab therapy is indicated, thereby facilitating optimal patient outcomes.

Participants gain comprehension of denosumab's pivotal role as a total human IgG2 monoclonal antibody. By selectively binding to the receptor activator of the NF kappa B ligand (RANKL), denosumab competently inhibits its interaction with the NF kappa B receptor activator (RANK). This inhibition forms the crux of its therapeutic efficacy in preventing bone resorption and mitigating associated risks. The content strategically navigates through pertinent aspects, empowering healthcare professionals to make informed decisions and contribute effectively to patient care within denosumab therapy.


Target Audience

This activity has been designed to meet the educational needs of physicians.

Learning Objectives

At the conclusion of this activity, the learner will be better able to:

  • Identify the appropriate indications for denosumab therapy in treating osteoporosis, metastatic bone disease, certain bone tumors, and treatment-induced bone loss.

  • Screen patients for eligibility and assess their suitability for denosumab therapy, considering factors such as medical history, concurrent medications, and potential contraindications.

  • Apply knowledge of the adverse effects of denosumab and proactively manage and monitor potential complications.

  • Implement effective communication with patients about denosumab therapy's benefits, risks, and expectations, ensuring informed and shared decision-making.

Disclosures

The Campbell University Jerry M. Wallace School of Osteopathic Medicine (CUSOM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they or their immediate family may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by CUSOM for resolution, to ensure fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

CUSOM will identify, review, and resolve all conflicts of interest that faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for authors, editors, planners, peer reviewers, and/or relevant staff is provided with this activity.

Continuing Education Accreditation Information

 

 

The Campbell University Jerry M. Wallace School of Osteopathic Medicine (CUSOM) is accredited by the American Osteopathic Association to provide osteopathic continuing medical education for physicians. CUSOM designates this enduring material for a maximum of 1.00 AOA Category 1 B Credits and will report CME credits commensurate with the extent of the physician's participation in the activity.

Cancellation Policy: Cancellations must be received in writing and a money back guarantee is provided if not completely satisfied.

  • StatPearls and CUSOM reserve the right to cancel any course due to unforeseen circumstances. StatPearls and CUSOM will not be responsible for other expenses incurred by the participant in the unlikely event that the program is canceled.

Equal Opportunity

  • StatPearls and CUSOM are Equal Opportunity / Affirmative Action / Equal Access Institutions. 

Medium or Media Used:

  • Computer Requirements:  Internet Access
  • E-mail Address

Instructions for Credit

  1. Register for the activity and create a StatPearls login.     
  2. Review the required accreditation information:  Target audience, learning objectives and disclosure information.
  3. Complete the entire self-study activity.
  4. Complete the post-test assessments.
  5. Successfully pass the post-test with a minimum score of 100%.
  6. Complete the evaluation form.
  7. Obtain a certificate.

StatPearls and CUSOM adheres to AOA Standards regarding commercial support of continuing medical education. It is the policy of StatPearls and Campbell that the faculty and planning committee disclose real or apparent conflicts of interest relating to the topics of this educational activity, that relevant conflict(s) of interest are resolved and also that authors and editors will disclose any unlabeled/unapproved use of drug(s) or device(s) during their presentation. Detailed disclosure will be made prior to starting the activity.

The information provided at this CME/CE activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

This course is intended for osteopathic physicians who wish to earn AOA CME credit. Take this version of the course to ensure you receive appropriate credit.

 

 
 

Reviews

Joseph B. on 10/30/2021

on 3/27/2022

Shannon j. on 7/25/2022

Clifford A. on 8/10/2022

Mary Y. on 8/28/2022

efstathia c. on 12/26/2022

Peter S. on 1/4/2023

Przemyslaw L. on 3/15/2023

James l. on 4/1/2023

Mary Y. on 4/10/2023

Sydney d. on 6/30/2023

Ashvini S. on 6/23/2023

Ronald D. on 7/13/2023

Dennis R. on 7/14/2023

Edgardo R. on 7/22/2023

Mohammad J. on 7/24/2023

Larry S. on 8/3/2023

None.

Richard P. on 9/4/2023

John T. on 9/22/2023

Erika G. on 1/16/2024

John L. on 2/26/2024

Gurdeep C. on 3/6/2024

Mark A. on 3/25/2024

Unlimited Physician CME

Stay up to date on the latest medical knowledge with 6673 CME activities. In these online self-assessment activities, read our reference articles and test your knowledge with more than 7923.5 hours of CME.

Learn About Lifetime CME

Single Activity

Take this single activity

$39 1 activity

6 Month Unlimited Physician CME

Access to all the Unlimited Physician CME activities in all specialties.

$399 per half year per user

1 Year Unlimited Physician CME

Access to all the Unlimited Physician CME activities in all specialties.

$599 per 1 year per user